Gocovri for Parkinson's Disease User Reviews
- SuzG
- Taken for 1 to 6 months
- December 7, 2023
"Gocovri has reduced the length of time of my dyskinesia and reduced the severity as well. I am forced to go off of it due to the cost. Seems like the cost could be reduced to have more users. I can't afford $900 per month and then the donut hole! Back to Amantadine IR."
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
Learn more about Parkinson's Disease
Care guides
Symptoms and treatments
Medicine.com guides (external)
More about Gocovri (amantadine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: dopaminergic antiparkinsonism agents
- Breastfeeding
- En español
"Gorcovi seemed to be better at controlling dyskinesia than Amantadine. There was less abdominal cramping in the morning. I was taking the 68.5 mg capsule which is the lowest dose before bedtime. However Gorcovi is very expensive. My co-pay was close to $450 per month. I felt the difference in comparing the two medications' ability to control the dyskinesia was not sufficient enough to warrant the excessive cost of Gorcovi."